Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barré Syndrome: A Randomized Trial

Abstract

Treatment with IVIG before loss of unaided walking did not give rise to a less severe course, but recovery occurred somewhat faster. However, given the small number of patients, the power of this conclusion is low. For treatment after loss of unaided walking, there was no significant difference in the effectiveness of 2 g/kg IVIG administered over 2 days versus 5 days. Early "relapses" occurred more frequently after the shorter treatment regimen.

Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders [RETIRED]

“…1 One Class II study examined 21 children with mild GBS able to walk 5 meters unassisted. 2 Fourteen children received treatment of 1 g/kg over 2 days; the remaining patients received no treatment (no blinding or sham treatment was used). There was no difference between groups in the primary outcome measure of disability at the disease nadir.…”

The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data

“…The disease course became shorter in those who received IVIG. No significant difference was detected between IVIG administration in 2 d or 5 d. 124 There are studies on the comparative evaluation of efficacy of IVIG vs. PE in pediatric patients affected by GBS. In regards, 7 children with GBS who were treated with IVIG (0.4 g/kg/day for 5 days) were prospectively evaluated.…”

Epidemiology of Childhood Guillain Barré Syndrome in Yemen

“…High rate of residual paralysis among GBS cases 60 days after paralysis onset may result in a misclassification Of GBS cases as confirmed polio and underscores the importance of virus isolation from adequate stools as the preferred method to confirm cases of polio [24]. The syndrome often begins with symmetric weakness of lower limbs [10]. However, ascending quick progression of weakness develops total motor paralysis and death may occur due to respiratory insufficiency [27].…”

“…Epidemiological studies from different areas estimate that the incidence of GBS ranges between 1 and 2/100,000 [10] [11]. In the United State of America, annual incidence of GBS is 1.2 -3/100,000 inhabitants.…”